Cargando…

Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies

In vitro amplified human leukocyte antigen (HLA)-haploidentical donor immune cell infusion (HDICI) is not commonly used in children. Therefore, our study sought to evaluate its safety for treating childhood malignancies. Between September 2011 and September 2012, 12 patients with childhood malignanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fei, Sun, Xiao-Fei, Li, Yong-Qiang, Zhen, Zi-Jun, Zheng, Hai-Xia, Zhu, Jia, Wang, Qi-Jing, Lu, Su-Ying, He, Jia, Wang, Juan, Pan, Ke, Cai, Rui-Qing, Chen, Yan, Weng, De-Sheng, Sun, Fei-Fei, Xia, Jian-Chuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sun Yat-sen University Cancer Center 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870850/ https://www.ncbi.nlm.nih.gov/pubmed/23706769 http://dx.doi.org/10.5732/cjc.012.10298

Ejemplares similares

Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies
por: Gao, Xiao-Ning, et al.
Publicado: (2018)

HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?
por: Ab Rahman, Syaza, et al.
Publicado: (2022)

Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report
por: Zhang, Cheng, et al.
Publicado: (2019)

A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients
por: Lu, Wenyi, et al.
Publicado: (2022)

Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation
por: Zhang, Rongli, et al.
Publicado: (2020)

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease
por: Scheiermann, Julia, et al.
Publicado: (2023)

Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia
por: Wang, Jing-Zhi, et al.
Publicado: (2021)

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
por: Castagna, Luca, et al.
Publicado: (2020)

Impact of Donor-Specific anti-HLA Antibodies and Donor KIR Characteristics in Haploidentical HSCT for Beta-Thalassemia
por: Andreani, Marco, et al.
Publicado: (2017)

Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor
por: Sun, Yu-Qian, et al.
Publicado: (2021)

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
por: Chang, Ying-Jun, et al.
Publicado: (2016)

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study
por: Chang, Ying-Jun, et al.
Publicado: (2020)

Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation
por: McCurdy, Shannon R., et al.
Publicado: (2015)

Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation
por: Kongtim, Piyanuch, et al.
Publicado: (2016)

Haploidentical Stem Cell Transplantation: A Gateway to Infrequent Availability of HLA-Matched Related Donors
por: Aslam, Hafiz Muhammad, et al.
Publicado: (2018)

Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG?
por: Weng, Guangyang, et al.
Publicado: (2022)

HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
por: Jin, Xin, et al.
Publicado: (2019)

Survival analysis of children with stage II testicular malignant germ cell tumors treated with surgery or surgery combined with adjuvant chemotherapy
por: Lu, Su-Ying, et al.
Publicado: (2015)

Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?
por: Perales, Miguel-Angel, et al.
Publicado: (2020)

1763. The Use of Haploidentical Donors Compared with HLA-Matched Unrelated Donors is Associated with Increased Risk of BK Viruria and Hemorrhagic Cystitis
por: Morgan. Scott, Mary, et al.
Publicado: (2019)

Therapy of severe aplastic anemia with anti-human thymocyte globulin (ATGAM) with and without HLA-haploidentical bone-marrow infusion.
por: Kim, K. Y.
Publicado: (1986)

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation
por: Williams, Louis, et al.
Publicado: (2020)

Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2020)

Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma
por: Smith, Jasmine, et al.
Publicado: (2021)

P1322: EFFECTS OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSA) FOR PRIMARY GRAFT FAILURE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA MAJOR
por: Liao, Jianyun, et al.
Publicado: (2023)

Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation
por: Yu, Xing-Xing, et al.
Publicado: (2022)

Tregs combined with mature donor T cells hasten immune reconstitution without triggering GvHD in HLA haploidentical transplantation
por: Di Ianni, Mauro, et al.
Publicado: (2011)

Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS
por: Michel, Claire, et al.
Publicado: (2023)

Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL
por: Yu, Changlin, et al.
Publicado: (2020)

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Dou, Li-Ping, et al.
Publicado: (2018)

Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study
por: Xu, Lan-Ping, et al.
Publicado: (2019)

Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings
por: Zhang, C, et al.
Publicado: (2010)

PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma—A Matched-Pair Analysis
por: Haebe, Sarah, et al.
Publicado: (2023)

Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis
por: Chang, Ying-Jun, et al.
Publicado: (2017)

T‐cell depleted HLA‐haploidentical HSCT in a child with neuromyelitis optica
por: Ceglie, Giulia, et al.
Publicado: (2019)

Brain toxoplasmosis after HLA haploidentical transplantation for acute myeloid leukemia
por: Tsushima, Takafumi, et al.
Publicado: (2022)

Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders
por: Albert, Michael H., et al.
Publicado: (2021)

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study
por: Zhang, Rui, et al.
Publicado: (2021)

Fast and covariate-adaptive method amplifies detection power in large-scale multiple hypothesis testing
por: Zhang, Martin J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hqfv42korenvesjanvfr5kf719